Borella F, Porpiglia M, Gallio N, Cito C, Boriglione L, Capella G
Curr Oncol. 2025; 32(2).
PMID: 39996866
PMC: 11854776.
DOI: 10.3390/curroncol32020066.
Deeban K, Gopinathan A, Bharathi A, G N
Cureus. 2024; 16(9):e68589.
PMID: 39371779
PMC: 11450233.
DOI: 10.7759/cureus.68589.
Bahrami M, Karami F, Hekmatnia A, Soltani S, Fadavi P, Hekmatnia F
J Res Med Sci. 2024; 29:37.
PMID: 39239077
PMC: 11376722.
DOI: 10.4103/jrms.jrms_587_22.
Alvarez B, Montero A, Ciervide R, Garcia-Aranda M, Valero J, Chen-Zhao X
Transl Breast Cancer Res. 2024; 4:19.
PMID: 38751466
PMC: 11093036.
DOI: 10.21037/tbcr-23-37.
Ranjbar A, Zangouri V, Shokripour M
BMC Cancer. 2024; 24(1):48.
PMID: 38195454
PMC: 10775459.
DOI: 10.1186/s12885-023-11805-2.
Differentiation between Phyllodes Tumors and Fibroadenomas through Breast Ultrasound: Deep-Learning Model Outperforms Ultrasound Physicians.
Shi Z, Ma Y, Ma X, Jin A, Zhou J, Li N
Sensors (Basel). 2023; 23(11).
PMID: 37299826
PMC: 10255878.
DOI: 10.3390/s23115099.
Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study.
Mo Q, Wang Y, Shan J, Wang X
Radiat Oncol. 2022; 17(1):119.
PMID: 35799256
PMC: 9264504.
DOI: 10.1186/s13014-022-02082-7.
A Signature of Three microRNAs Is a Potential Diagnostic Biomarker for Glioblastoma.
Hosein Yazdi A, Zarrinpour V, Moslemi E, Forghanifard M
Iran Biomed J. 2022; 26(4):301-12.
PMID: 35490305
PMC: 9432466.
DOI: 10.52547/ibj.3671.
Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.
OConnor D, Davey M, Barkley L, Kerin M
Breast. 2021; 61:1-10.
PMID: 34864494
PMC: 8649952.
DOI: 10.1016/j.breast.2021.11.017.
Identification of a six-microRNA signature as a potential diagnostic biomarker in breast cancer tissues.
Mahmoudian M, Razmara E, Hussen B, Simiyari M, Lotfizadeh N, Motaghed H
J Clin Lab Anal. 2021; 35(11):e24010.
PMID: 34528314
PMC: 8605139.
DOI: 10.1002/jcla.24010.
Phyllodes Tumors of the Breast: A Literature Review.
Rayzah M
Cureus. 2020; 12(9):e10288.
PMID: 32923300
PMC: 7478785.
DOI: 10.7759/cureus.10288.
Secretory breast carcinoma in a male child: Case report and literature review.
Kluppel E, Rodrigues da Costa L, Marquetto Tognolo C, do Nascimento A, Ribeiro M, Fachin C
Int J Surg Case Rep. 2020; 73:310-314.
PMID: 32736235
PMC: 7394736.
DOI: 10.1016/j.ijscr.2020.07.040.
Omission of Chemotherapy for the Treatment of Mucinous Breast Cancer: A Nationwide Study from the Korean Breast Cancer Society.
Kim H, Lee J, Yoo T, Chae B, Son D, Kim Y
J Breast Cancer. 2020; 22(4):599-612.
PMID: 31897333
PMC: 6933040.
DOI: 10.4048/jbc.2019.22.e46.
Giant Mucinous Carcinoma of the Breast.
Alothman S, Saeed S, Khan K, Ramcharan A, DePaz H
Cureus. 2019; 10(11):e3606.
PMID: 30680267
PMC: 6338408.
DOI: 10.7759/cureus.3606.
Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer.
Mayer S, Erbes T, Timme-Bronsert S, Jaeger M, Rucker G, Kuf F
Oncol Lett. 2017; 14(2):2334-2340.
PMID: 28789451
PMC: 5529991.
DOI: 10.3892/ol.2017.6406.
Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer.
Cedolini C, Bertozzi S, Londero A, Seriau L, Andretta M, Agakiza D
Int J Clin Exp Pathol. 2016; 8(10):13304-13.
PMID: 26722534
PMC: 4680479.
Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.
Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera A, Arun B
Biomark Cancer. 2015; 7:39-49.
PMID: 26327783
PMC: 4541461.
DOI: 10.4137/BIC.S29716.
Expression of Prostacyclin-Synthase in Human Breast Cancer: Negative Prognostic Factor and Protection against Cell Death In Vitro.
Klein T, Benders J, Roth F, Baudler M, Siegle I, Komhoff M
Mediators Inflamm. 2015; 2015:864136.
PMID: 26265889
PMC: 4526217.
DOI: 10.1155/2015/864136.
Race is not a factor in overall survival in patients with triple negative breast cancer: a retrospective review.
Starlard-Davenport A, Glover-Collins K, Mahkoul I, Hutchins L, Westbrook K, Korourian S
Springerplus. 2015; 2:516.
PMID: 25674397
PMC: 4320183.
DOI: 10.1186/2193-1801-2-516.
A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F, Ding X, Fan Y, Ying J, Zheng S, Lu N
PLoS One. 2014; 9(11):e112765.
PMID: 25393310
PMC: 4231092.
DOI: 10.1371/journal.pone.0112765.
